Promising Phase 1‑2 results have put Chinese researchers on the brink of a major win against pancreatic cancer, often called the “king of cancer.” If Phase 3 confirms the early data, new targeted medicines could soon be approved, giving patients fresh treatment options. One breakthrough focuses on the KRAS G12C mutation; scientists discovered that hitting two molecular pathways at once dramatically shrank tumors in lab studies. When they approached a drug maker that was developing those agents for lung cancer, the company pivoted to pancreatic trials, now entering Phase 3. The synergy between home‑grown drug firms and clinicians is also opening doors for immunotherapy. Pancreatic tumors are “cold” because dense scar tissue blocks immune cells, but the new targeted drugs are cracking that barrier, allowing checkpoint inhibitors to work more effectively. Radiation therapy is getting a boost, too. Heavy‑ion beams—thanks to their precise “Bragg peak” energy release—damage cancer cells while sparing surrounding tissue, and a decade of data backs their safety. Experts also stress everyday prevention: a high‑protein, vitamin‑rich, low‑sugar diet; quitting smoking and limiting alcohol; maintaining a healthy weight; managing stress and sleep. High‑risk individuals—those with a family history, new‑onset diabetes, long‑standing diabetes, chronic pancreatitis, or pancreatic cysts—should get an annual thin‑slice CT scan with contrast.
Read moreBayer has secured approval for its oral tablet Herxinuo® (savolitinib) in China, marking the first targeted therapy specifically designed for patients with HER2‑mutated non‑small cell lung cancer (NSCLC). The drug’s approval follows the promising results of the SOHO‑01 clinical trial, which showed strong efficacy and a manageable safety profile in people with advanced or metastatic disease carrying HER2‑activating mutations. Herxinuo® offers a much‑needed option for a group that previously had very limited treatment choices. Bayer executives highlighted the pill as a “precision weapon” that aligns with the company’s focus on personalized oncology solutions and its commitment to improving survival and quality of life for Chinese lung‑cancer patients. The approval reflects growing global interest in HER2‑targeted strategies, supported by earlier research identifying driver gene signatures in Chinese NSCLC patients and pre‑clinical studies of similar compounds. While the medication is now available, the site reminds readers that it does not replace professional medical advice. For diagnosis or treatment decisions, patients should consult their healthcare providers.
Read more